RESUMEN
In the article data are presented about morbidity by oncogematologic pathology - one of the most meaningful of social-economic problems. In Ukraine annually diagnose the to 8 thousand new cases of haemoblastosis. Indexes of morbidity on a 100 thousand population are 5,2; at illness of Hodgkin's lymphoma - 2,5, at plural myeloma - 1,6; at leukemia - 8,1. Morbidity by haematological pathology in Kyiv long time remains high: annually 250 expose patients with malignant lymphnoma, 57 - with myeloma, 190 - with leukemia, from them at 55 % is a sharp form and at 40 % - chronic. The anxiety of doctors causes circumstance that the special treatment is overcome 58,1 % patients by leukemia, 68,6 % - plural myeloma and 77,8 % patients with malignant lymphoma. World experience shows that application of complex methods of therapy allows to prolong life-span 80-90 % patients with Hodgkin's malignant lymphoma on 10, and at 95 % patients by a lymphogranulomatosis - to attain nonrecurrence survival to 5 years.
Asunto(s)
Atención a la Salud/estadística & datos numéricos , Leucemia Linfoide/terapia , Leucemia Mieloide/terapia , Linfoma/terapia , Adolescente , Adulto , Atención a la Salud/organización & administración , Femenino , Humanos , Leucemia Linfoide/clasificación , Leucemia Linfoide/mortalidad , Leucemia Linfoide/patología , Leucemia Mieloide/clasificación , Leucemia Mieloide/mortalidad , Leucemia Mieloide/patología , Linfoma/clasificación , Linfoma/mortalidad , Linfoma/patología , Masculino , Persona de Mediana Edad , Análisis de Supervivencia , UcraniaRESUMEN
Galectines are a family of carbohydrate-binding proteins with an affinity for beta-galactosides. Galectines is differentially expressed by various normal and pathological tissues and appears to be functionally polyvalent, with a wide range of biological activity. The intracellular and extracellular activity of galectines has been described. Evidence points to galectin and its ligands as one of the master regulators of such immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host-pathogen interactions. Galectines expression or overexpression in tumors and/or the tissue surrounding them must be considered as a sign of the malignant tumor progression that is often related to the long-range dissemination of tumoral cells (metastasis), to their dissemination into the surrounding normal tissue, and to tumor immune-escape. Elevated levels of galectines have been found to be significantly associated with higher risk progressing of the lymphoproliferative disease. The targeted inhibition of Galectines expression is what should be developed for therapeutic applications against cancer progression. Galectines are the promising molecular target for the development of new and original diagnostic and therapeutic tools.
Asunto(s)
Biomarcadores de Tumor/genética , Galectinas/genética , Regulación Neoplásica de la Expresión Génica , Neoplasias Hematológicas/genética , Trastornos Linfoproliferativos/genética , Proteínas de Neoplasias/genética , Biomarcadores de Tumor/inmunología , Biomarcadores de Tumor/metabolismo , Galactósidos/metabolismo , Galectinas/inmunología , Galectinas/metabolismo , Neoplasias Hematológicas/diagnóstico , Neoplasias Hematológicas/inmunología , Humanos , Ligandos , Trastornos Linfoproliferativos/diagnóstico , Trastornos Linfoproliferativos/inmunología , Proteínas de Neoplasias/inmunología , Proteínas de Neoplasias/metabolismo , Pronóstico , Unión Proteica , Transducción de Señal , Escape del TumorRESUMEN
The article presents findings of the analysis on P-glycoprotein expression of leukemic cells in 52 acute myeloid leukemia (AML) patients. Of these, there were 20 persons exposed to ionizing radiation due to the Chernobyl accident and 32 patients with spontaneous disease. Leukemic cells in patients with radiation-associated AML compared to spontaneous cases more often were P-glycoprotein positive (12/20 vs 9/32, P<0,05). P-glycoprotein overexpression significantly correlated with resistant disease in patients with radiation-associated AML, but was not a prognostic variable for treatment outcome in terms of overall survival.